Aristo Bio-Tech & Lifescience Ltd Financials
Company Logo

Aristo Bio-Tech & Lifescience Ltd Financial Statement

Aristo Bio-Tech & Lifescience Ltd Income Statement

Quarterly

Annual

*All values are in Rs. Cr

No Data Available

Aristo Bio-Tech & Lifescience Ltd Profit & Loss

*All values are in Rs. Cr

Standalone

Consolidated

Particulars
Mar 2025
Total Revenue Annual318.09
Operating Expenses Annual308.82
Operating Profit Annual9.73
Interest Annual1.66
Depreciation2.60
Net Profit Annual4.06
Tax Annual1.40

Aristo Bio-Tech & Lifescience Ltd Cash Flow

*All values are in Rs. Cr

Standalone

Consolidated

Particulars
Mar 2025
Cash Flow at the Beginning0.64
Cash Flow from Operations10.02
Cash Flow from Investing-5.15
Cash Flow from Financing-4.39
Cash Flow at the End1.12

Aristo Bio-Tech & Lifescience Ltd Key Ratios

*All values are in Rs. Cr

Standalone

Consolidated

Particulars
Mar 2025
PBDIT Margin (%)3.06
PBIT Margin (%)2.24
PBT Margin (%)0.89
Net PROFIT Margin (%)1.28
Return On Networth / Equity (%)11.45
Return On Networth /Employed (%)12.53
Return On Assets (%)7.15
Total Debt / Equity (X)0.60
Asset Turnover Ratio (%)5.60

Aristo Bio-Tech & Lifescience Ltd Balance Sheet

*All values are in Rs. Cr

Standalone

Consolidated

Particulars
Mar 2025
Fixed Assets Annual23.95
Total Current Assets Annual115.76
Non Current Assets Annual24.86
Total Shareholders Funds Annual37.33
Total Assets Annual140.62

Aristo Bio-Tech & Lifescience Ltd Earning Calls

No Data Availabe

FAQS on Aristo Bio-Tech & Lifescience Ltd Financials

As of Sep 6, 2025, Aristo Bio-Tech & Lifescience Ltd has a market capitalization of 79.11 Cr. Value Research classifies it as a Micro-Cap company.

Yes, Aristo Bio-Tech & Lifescience Ltd is not with a debt-to-equity ratio of 0.59.

In FY 2024 , Aristo Bio-Tech & Lifescience Ltd recorded a total revenue of approximately 318.09 Cr marking a significant milestone in the company's financial performance.

Aristo Bio-Tech & Lifescience Ltd's Future outlook anticipates robust growth, with forecasted earnings and revenue rising approximately 0.4% and 0.2% annually, respectively..

Aristo Bio-Tech & Lifescience Ltd's current PE ratio is 19.49.

Aristo Bio-Tech & Lifescience Ltd's ROCE averaged 13.1% from the FY ending March 2023 to 2025, with a median of 13.0%. It peaked at 14.2% in March 2023, reflecting strong capital efficiency over the period..

Aristo Bio-Tech & Lifescience Ltd's latest EBIT is Rs. 7.13 Cr, surpassing the average EBIT of Rs. 7.24 Cr over the 5 years..

Join the Future of Trading

with BlinkX

#ItsATraderThing

Open Trading Account
Verify your phone
+91
*By signing up you agree to our terms & conditions